<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157546/" ref="ordinalpos=822&amp;ncbi_uid=3509078&amp;link_uid=PMC3157546" image-link="/pmc/articles/PMC3157546/figure/F7/" class="imagepopup">Figure 7.  From: TAK1-TAB2 <span class="highlight" style="background-color:">signaling</span> contributes to bone destruction by breast carcinoma cells. </a></div><br /><div class="p4l_captionBody">Model for the role of TAK1 signaling in bone metastasis. (<b>A</b>) TGF-β and pro-inflammatory cytokines can activate TAK1 in tumor cells. TAK1 is likely to interact with the TAB2/TAB3-TRAF complex leading to activation of NFkB and up-regulation of MMP-9, COX2, IL8 and PTHrP. Expression of dnTAK1 (TAK1-K63W) hinders this signaling pathway in tumor cells. (<b>B</b>) In bone environment, the TAK1 signaling pathway in tumor cells promotes the “vicious cycle” leading to the disproportionate activity of osteoclasts and bone destruction.</div></div>